Revision Skincare Validates Vitamin C Serum in Clinical Studies
IRVING, Texas, April 9, 2026 Revision Skincare® has announced the publication of two peer-reviewed clinical studies in the Journal...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
IRVING, Texas, April 9, 2026 Revision Skincare® has announced the publication of two peer-reviewed clinical studies in the Journal...
San Francisco, USA | March 28, 2026 Phase 2b Data Demonstrates Strong Clinical Efficacy Nektar Therapeutics has announced compelling...
Sacramento, California | February 19, 2026 — KilgourMD announced results from an independent Phase II clinical trial evaluating its...
